Skip to main content
Premium Trial:

Request an Annual Quote

James Mullen

Thermo Fisher Scientific's board has elected James Mullen as a director, effective Nov. 8. He was appointed to the board's strategy and financing committee, and his term expires at the 2019 annual meeting. Mullen was CEO of Patheon until that firm's acquisition by Thermo Fisher in August 2017. Prior to Patheon, he was CEO and president of Biogen. 

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.